COPD Assessment Test (CAT) is a valid and simple tool to measure the impact of bronchiectasis on affected patients

The COPD assessment test (CAT) is a short questionnaire developed to help patients and clinicians to assess the impact of symptoms in routine clinical practice. We aimed to validate and to test the reproducibility of CAT in patients with bronchiectasis and correlate with the severity of dyspnea, aer...

Descripción completa

Detalles Bibliográficos
Autores: Fernanda de Córdoba Lanza, Rejane Agnelo Silva de Castro, Anderson Alves de Camargo, Drielly Jésica Milani Zanatta, Samia Zahi Rached, Rodrigo Abensur Athanazio, Alberto Cukier, Rafael Stelmach, Simone Dal Corso
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2018
País:Brasil
Institución:Universidade Federal de Minas Gerais (UFMG)
Repositorio:Repositório Institucional da UFMG
Idioma:inglés
OAI Identifier:oai:repositorio.ufmg.br:1843/46984
Acceso en línea:https://doi.org./10.1080/15412555.2018.1540034
http://hdl.handle.net/1843/46984
https://orcid.org/0000-0002-4748-6947
https://orcid.org/0000-0002-5524-3371
https://orcid.org/0000-0002-0353-875X
https://orcid.org/0000-0001-6741-1320
https://orcid.org/0000-0002-9399-5275
https://orcid.org/0000-0002-7217-9498
https://orcid.org/0000-0002-5132-1934
https://orcid.org/0000-0001-9190-6796
Access Level:acceso abierto
Palabra clave:Bronchiectasis
COPD
Respiratory function
Quality of life
Cough
Bronquiectasia
Doença pulmonar obstrutiva crônica
Respiração - Medição
Qualidade de vida
Tosse
Descripción
Sumario:The COPD assessment test (CAT) is a short questionnaire developed to help patients and clinicians to assess the impact of symptoms in routine clinical practice. We aimed to validate and to test the reproducibility of CAT in patients with bronchiectasis and correlate with the severity of dyspnea, aerobic and functional capacity, and physical activity in daily life. This is a cross-sectional study, patients with bronchiectasis underwent spirometry, cardiopulmonary exercise test (CPET), incremental shuttle walk test (ISWT), Saint George`s Respiratory Questionnaire (SGRQ), and received pedometer. CAT was applied twice (CAT-1 and CAT-2, 7 to 10 days apart). The severity of bronchiectasis was assessed by E-FACED and bronchiectasis severity index (BSI). A total of 100 patients were evaluated (48 ± 14 years, 59 women, FVC: 67 ± 22% pred, FEV1: 52 ± 25% pred). According to CAT, 14% patients presented low, 40% medium, 32% high, and 14% very high impact. The higher the CAT, the worse the severity of bronchiectasis, dyspnea, quality of life, performance on the CPET, and smaller the distance walked (DW) on the ISWT and number of steps (NS) per day. There was significant correlation between CAT and SGRQ, E-FACED, BSI, NS, ISWT, oxygen uptake, and workload at CPET. CAT-1 and CAT-2 presented similar values: 21 (13–26) and 19 (13–26), respectively. The CAT is a valid and reproducible instrument in patients with bronchiectasis presenting good correlation with clinical, functional, and quality of life measurements. This easy-to-use, easy-to-understand, quick, and useful tool may play an important role to assess the impact of bronchiectasis on both daily medical practice and clinical trial settings.